|
On February 3, 2005, the U.S. Food and Drug Administration approved orphan drug status for Proxinium (VB4-845), made by Viventia Biotech, Inc. The drug is intended to treat advanced, recurrent head and neck cancer, including cancers of the larynx, tongue, mouth, oral cavity, and pharynx. Only a small number of these tumors can be surgically treated, usually with high complication rates. Radiation or canonical chemotherapy treatments may not be efficacious. Read the press release . |
